Evolution-Inspired drug sequence aims to outsmart breast cancer

NCT ID NCT06409390

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a new way of giving several already-approved chemotherapy drugs in a specific order to treat hormone-positive metastatic breast cancer. The idea is to hit the cancer with a 'first strike' and then a 'second strike' to make treatment more effective. The study will enroll 15 women to see if this approach is practical and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Docetaxel, Cyclophosphamide, Trastuzumab deruxtecan, Sacituzumab govitecan, Capecitabine, Fulvestrant
What this could lead to: If successful, this approach could offer a more effective way to control metastatic breast cancer by using existing drugs in a strategic sequence.
What could go wrong: This is a very small pilot study with only 15 participants, so results may not apply broadly. The treatment involves multiple chemotherapy drugs with known side effects like fatigue, nausea, and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.